Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 99 | ECE2024 | Next issue

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

Card image cap
We are pleased to announce that ECE 2024 will be held in Stockholm, Sweden from 11-14 May 2024. We will, once again, be offering the hybrid format next year so you can join us in person in Sweden or remotely with ECE@Home.

Oral Communications

Oral Communications 9: Pituitary and Neuroendocrinology | Part II

ea0099oc9.1 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Differential gene expression in dopamine agonist sensitive and resistant human prolactinomas

Delgrange Etienne , Trouillas Jacqueline , Wierinckx Anne

Dopamine agonists (DAs) are usually used as first line treatment in prolactinomas. Some tumors do not normalize prolactin levels under treatment and demonstrate a more aggressive course. The mechanisms underlying this chemoresistance are poorly understood. Previous gene expression studies have focused on candidate genes such as the DA receptor 2 (DRD2) or the nerve growth factor (NGF), but transcriptome analyses comparing tumors resistant and responsive to DA are still lacking...

ea0099oc9.2 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Successful breastfeeding in a parturient with panhypopituitarism: A case report and literature review with implications for endocrine practice

Derdikman Ofir Yael , Eglash Anne , Moberg Kerstin , Hochberg Irit

Panhypopituitarism is a complex endocrine condition often thought to preclude breastfeeding due to its inherent hormonal deficiencies. Breastfeeding, however, is an important health behavior that reduces maternal morbidity and mortality. Breastfeeding reverses cardiometabolic risk factors acquired during pregnancy by reducing visceral fat and cholesterol, lowering risks of type 2 diabetes, cardiovascular and neurovascular comorbidity, and breast and ovarian cancer. We report o...

ea0099oc9.3 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Loss of heterozygosity predicts treatment-refractory behavior in pituitary neuroendocrine tumors

Lin Andrew , Rudneva Vasilisa , Richards Allison , Zhang Yanming , Rosenblum Marc , Donoghue Mark , Tabar Viviane , Geer Eliza

Background: Pituitary neuroendocrine tumors (PitNETs) exhibiting treatment-refractory behavior are the rare subset that progress after radiation and are characterized by unrelenting growth and metastatic dissemination.Methods: To identify biomarkers of treatment-refractory behavior, two groups of patients with PitNETs were consented to matched tumor-normal whole exome and targeted next-generation DNA sequencing on a clinical protocol: a prospective group...

ea0099oc9.4 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Kisspeptin administration does not alter anxiety or circulating cortisol levels in humans

Mills Edouard G , Thurston Layla , Yang Lisa , Suladze Sofiya , Hunjan Tia , Phylactou Maria , Patel Bijal , Clarke Sophie A. , Shah Amar J. , Izzi-Engbeaya Chioma , Tsoutsouki Jovanna , Bech Paul , Ertl Natalie , Demetriou Lysia , Wall Matthew B. , Goldmeier David , Abbara Ali , Comninos Alexander N. , Dhillo Waljit S.

Background: The neuropeptide kisspeptin is a key endogenous activator of the reproductive system. Due to its crucial role in modulating reproductive and behavioural processes, there has been accelerating interest in targeting kisspeptin-pathways to treat reproductive and psychosexual disorders. However, contradictory pre-clinical data from animal models suggests that kisspeptin can have an anxiolytic, anxiogenic or have no effects on anxiety. Given the rapid development of kis...

ea0099oc9.5 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Defining the role of androgen signalling in GABA neurons in the development of PCOS-like traits

Coyle Christopher , Prescott Melanie , Potapov Kyoko , Campbell Rebecca

Androgen excess is a hallmark feature of polycystic ovary syndrome (PCOS), the most common form of anovulatory infertility. Clinical and preclinical evidence links developmental exposure to hyperandrogenism with programming the reproductive traits of PCOS. While the critical androgen targets remain to be determined, GABAergic neurons in the brain are postulated to be involved. GABA levels are elevated in the cerebrospinal fluid of PCOS patients, and both GABA transmission and ...

ea0099oc9.6 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Antiproliferative role of the vasopressin V2 receptor antagonist tolvaptan in a murine xenograft model of small cell lung cancer

Marroncini Giada , Naldi Laura , Polvani Simone , Pasella Francesca , Cirillo Chiara , Fibbi Benedetta , Peri Alessandro

Vaptans are nonpeptide vasopressin receptors antagonists, developed for the treatment of euvolemic or hypervolemic hyponatremia. Among them, tolvaptan, a selective V2receptors antagonist, approved for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuresis, was also approved for the treatment of polycystic kidney disease. Here, tolvaptan is able to reduce the growth of renal cysts and the rate of estimated glomerular filtration decrease...